Climb Bio, Inc. CLYM
We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet need for patients living with immune-mediated diseases. We have built our pipeline by strategically acquiring or in-licensing product candidates that we believe have clear biological rationale, well-defined development pathways, and the potential to address multiple indications.
We are developing our product candidates for multiple immune-mediated diseases, as summarized in the pipeline figure below.
We acquired the rights to our product candidates through license and asset purchase agreements. We have worldwide rights to develop and commercialize budoprutug for all indications, except for oncology. We have rights to develop and commercialize CLYM116 for all indications worldwide outside of mainland China, Hong Kong, Macau, and Taiwan, which we refer to as Greater China.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D | $46.7M | $14.3M | $15.4M | $26.2M | $23.3M | $8.8M | — |
| SG&A | $21.2M | $16.0M | $24.9M | $18.9M | $12.3M | $2.4M | — |
| Total operating expenses | $67.9M | $82.0M | $40.3M | $45.1M | $35.7M | $20.9M | — |
| Operating income | -$67.9M | -$82.0M | -$40.3M | -$45.1M | -$35.7M | -$20.9M | — |
| Pre-tax income | -$59.9M | -$73.9M | -$35.1M | -$45.2M | -$47.5M | -$20.7M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$59.9M | -$73.9M | -$35.1M | -$45.2M | -$47.5M | -$20.7M | — |
| EPS, basic | -0.88 | -1.53 | -1.30 | -1.72 | -4.24 | — | — |
| EPS, diluted | -0.88 | -1.53 | -1.30 | -1.72 | -4.24 | -10.49 | — |
| Shares, diluted (wtd. avg.) | $67.8M | $48.2M | $27.0M | $26.3M | $12.3M | $2.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $35.7M | $87.2M | $93.1M | $43.6M | $46.9M | $20.5M | $21.2M |
| Short-term investments | $65.4M | $63.7M | $13.7M | $80.0M | $89.6M | $0 | — |
| Total current assets | $105.8M | $154.9M | $110.3M | $134.4M | $148.3M | $22.0M | — |
| Property, plant and equipment | $288.0K | $199.0K | — | — | — | — | — |
| Total assets | $167.7M | $217.2M | $110.5M | $135.0M | $173.2M | $24.6M | — |
| Accounts payable | $2.3M | $705.0K | $66.0K | $750.0K | $1.4M | $1.1M | — |
| Total current liabilities | $7.0M | $4.9M | $2.8M | $6.1M | $6.0M | $3.1M | — |
| Total liabilities | $7.3M | $5.3M | $2.9M | $6.3M | $6.0M | $3.1M | — |
| Retained earnings | -$289.7M | -$229.9M | -$156.0M | -$120.9M | -$75.6M | -$28.1M | — |
| Total equity | $160.5M | $211.9M | $107.6M | $128.7M | $167.2M | -$25.0M | -$5.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$54.4M | -$15.6M | -$20.6M | -$37.4M | -$36.1M | -$14.1M | — |
| Depreciation and amortisation | $97.0K | $0 | — | — | — | — | — |
| Stock-based compensation | $8.1M | $5.6M | $12.8M | $7.0M | $3.7M | $707.0K | — |
| Capital expenditure | $186.0K | $0 | $0 | — | — | — | — |
| Investing cash flow | $2.8M | -$121.1M | $69.0M | $34.4M | -$115.0M | $8.1M | — |
| Financing cash flow | -$21.0K | $130.7M | $841.0K | $0 | $177.2M | $4.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-092546.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |